Succinimide compounds seem to be 2.4–2.3 times more powerful AChE inhibitors than rivastigmine, which is a commonly used drug for Alzheimer’s disease and has an IC50 value of 71,000 μM. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.